KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Amortizatization of Intangibles (2021 - 2025)

Bionano Genomics' Amortizatization of Intangibles history spans 5 years, with the latest figure at -$338000.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 228.03% year-over-year to -$338000.0; the TTM value through Sep 2025 reached -$819000.0, down 158.25%, while the annual FY2024 figure was $204000.0, 62.15% down from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was -$338000.0 at Bionano Genomics, down from $440000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $861000.0 in Q2 2024 and bottomed at -$972000.0 in Q4 2024.
  • The 5-year median for Amortizatization of Intangibles is $51000.0 (2022), against an average of $17312.5.
  • The largest annual shift saw Amortizatization of Intangibles tumbled 4342.11% in 2022 before it soared 4205.0% in 2024.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $19000.0 in 2021, then crashed by 4342.11% to -$806000.0 in 2022, then skyrocketed by 128.54% to $230000.0 in 2023, then tumbled by 522.61% to -$972000.0 in 2024, then skyrocketed by 65.23% to -$338000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Amortizatization of Intangibles are -$338000.0 (Q3 2025), $440000.0 (Q2 2025), and $51000.0 (Q1 2025).